JP2024528029A5 - - Google Patents
Info
- Publication number
- JP2024528029A5 JP2024528029A5 JP2024505205A JP2024505205A JP2024528029A5 JP 2024528029 A5 JP2024528029 A5 JP 2024528029A5 JP 2024505205 A JP2024505205 A JP 2024505205A JP 2024505205 A JP2024505205 A JP 2024505205A JP 2024528029 A5 JP2024528029 A5 JP 2024528029A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- optionally
- nucleic acid
- acid molecule
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227116P | 2021-07-29 | 2021-07-29 | |
| US63/227,116 | 2021-07-29 | ||
| PCT/IB2022/057006 WO2023007431A1 (en) | 2021-07-29 | 2022-07-28 | Engineered immune cell that specifically targets mesothelin and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528029A JP2024528029A (ja) | 2024-07-26 |
| JP2024528029A5 true JP2024528029A5 (enExample) | 2025-08-01 |
Family
ID=83457041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505205A Pending JP2024528029A (ja) | 2021-07-29 | 2022-07-28 | メソテリンを特異的に標的とする操作された免疫細胞及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240350627A1 (enExample) |
| EP (1) | EP4377335A1 (enExample) |
| JP (1) | JP2024528029A (enExample) |
| KR (1) | KR20240040068A (enExample) |
| CN (1) | CN117642421A (enExample) |
| AU (1) | AU2022318416A1 (enExample) |
| CA (1) | CA3227581A1 (enExample) |
| TW (1) | TW202321287A (enExample) |
| WO (1) | WO2023007431A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3845654A4 (en) * | 2018-08-31 | 2022-05-11 | Noile-Immune Biotech, Inc. | Car-expressing t cells and car expression vector |
| JP7818837B2 (ja) * | 2020-10-28 | 2026-02-24 | ティエスディ・ライフ・サイエンシーズ・カンパニー・リミテッド | 異種免疫細胞に対する化学走性を誘導する形質転換された免疫細胞 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP2928287B2 (ja) | 1988-09-29 | 1999-08-03 | 協和醗酵工業株式会社 | 新規ポリペプチド |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| EP4541818A3 (en) | 2012-05-25 | 2025-07-23 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| CN106459915A (zh) | 2014-02-04 | 2017-02-22 | 凯德药业公司 | 用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物 |
| US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| DK3597742T3 (da) * | 2014-10-09 | 2022-10-03 | Univ Yamaguchi | Car-udtrykkende vektor og car-udtrykkende t-celler |
| AU2017235116B2 (en) | 2016-03-17 | 2019-11-07 | Yamaguchi University | Immunocompetent cell and expression vector expressing regulatory factors of immune function |
| EP3695846B1 (en) * | 2017-10-10 | 2023-11-29 | Yamaguchi University | Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cells |
| FI3730612T3 (fi) * | 2017-12-24 | 2026-04-30 | Noile Immune Biotech Inc | Immunokompetentti solu, joka ilmaisee erityisesti ihmisen mesoteliinin, il-7:n ja ccl19:n tunnistavan solukalvon molekyylin |
-
2022
- 2022-07-28 CN CN202280050120.5A patent/CN117642421A/zh active Pending
- 2022-07-28 KR KR1020247000845A patent/KR20240040068A/ko active Pending
- 2022-07-28 EP EP22777698.6A patent/EP4377335A1/en active Pending
- 2022-07-28 JP JP2024505205A patent/JP2024528029A/ja active Pending
- 2022-07-28 WO PCT/IB2022/057006 patent/WO2023007431A1/en not_active Ceased
- 2022-07-28 CA CA3227581A patent/CA3227581A1/en active Pending
- 2022-07-28 TW TW111128411A patent/TW202321287A/zh unknown
- 2022-07-28 AU AU2022318416A patent/AU2022318416A1/en active Pending
- 2022-07-28 US US18/292,586 patent/US20240350627A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034244A1 (en) | Bicistronic chimeric antigen receptors and their uses | |
| CN110872577B (zh) | 修饰的免疫细胞及其应用 | |
| JP2024528052A5 (enExample) | ||
| JP6426713B2 (ja) | Ｇｐｃ３キメラ抗原受容体蛋白質をコードする核酸及びｇｐｃ３キメラ抗原受容体蛋白質を発現するｔリンパ球 | |
| AU2019235926A1 (en) | Anti-CD33 chimeric antigen receptors and their uses | |
| CN115698072B (zh) | 抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体 | |
| WO2017219936A1 (zh) | 一种高效稳定表达激活型抗体的car-t细胞及其用途 | |
| CN111349178A (zh) | 一种靶向gpc3的嵌合抗原受体(car)及其抗癌的用途 | |
| Li et al. | Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments | |
| CN108367068A (zh) | 用于治疗白血病的抗-s100a8 | |
| CN111944054A (zh) | 抗bcma的car及其表达载体和应用 | |
| JP2022525099A5 (enExample) | ||
| JP2024510898A (ja) | Ｒｏｒ１を標的とするキメラ抗原受容体 | |
| CN116568709A (zh) | 靶向cd5的全人源抗体、全人源嵌合抗原受体（car）及其应用 | |
| CN116554327A (zh) | 特异性结合c-Met的抗体、嵌合抗原受体及其应用 | |
| CN117003897B (zh) | 靶向Claudin18.2的CAR-T细胞及其用途 | |
| CN110386987A (zh) | 一种抑制性的合成Notch和双靶点系统及其制备方法和应用 | |
| TW202003854A (zh) | 抗人ｌａｇ－３單克隆抗體及其應用 | |
| CN111944053B (zh) | 抗bcma的car及其表达载体和应用 | |
| CN114685675B (zh) | 双特异性抗体及其在治疗癌症中的用途 | |
| CN116284419A (zh) | 靶向人gucy2c蛋白的单克隆抗体及其应用 | |
| CN120882754A (zh) | 用淋巴毒素β受体激动剂治疗癌症的方法 | |
| Pantuck et al. | Next generation T-cell therapy for genitourinary malignancies, part A: Introduction and current state of the art | |
| WO2023076811A1 (en) | Combination therapies with chimeric antigen receptors | |
| JP2023521218A (ja) | Ｃｄ２２標的キメラ抗原受容体、その調製方法、及びその適用 |